Loading…
Employees: 1,304
Size Japan Lifeline (7575.T) is a Japan Health Care company (Medical Specialties) with a market value of $685M, the 911th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,629 on 6 Nov 2026.
Performance Over six months the shares gained 16.0%, against -9.1% for the median peer and +1.8% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +9.3%); the operating margin is 18.7% (peer median 10.6%).
Valuation It trades at 14.1× forward earnings against a peer median of 24.3× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥61.3B | ¥59.2B | ¥56.6B | ¥51.4B | ¥51.8B |
| Revenue growth | — | +5% | +10% | -1% | — |
| Gross profit | ¥35.6B | ¥34.5B | ¥33.1B | ¥30.4B | ¥29.0B |
| EBITDA | ¥13.2B | ¥14.4B | ¥14.6B | ¥12.8B | ¥12.7B |
| Net income | ¥9.01B | ¥9.35B | ¥9.32B | ¥7.51B | ¥6.89B |
| Free cash flow | n/a | ¥6.27B | ¥7.56B | ¥4.79B | ¥10.7B |
| Capital expenditure | n/a | ¥1.97B | ¥1.99B | ¥2.34B | ¥1.73B |
| Total debt | ¥2.90B | ¥3.12B | ¥3.97B | ¥4.63B | ¥6.88B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7575.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.4% | -1.4% | 4th highest of 21 |
| 6-month return | +16.0% | -9.1% | 6th highest of 21 |
| Distance from 52-week high | -4.5% | -32.7% | highest of 21 |
| Revenue growth (TTM) | +5.8% | +9.3% | 9th lowest of 21 |
| Operating margin | 18.7% | 10.6% | 6th highest of 21 |
| Forward P/E | 14.1× | 24.3× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -9.7% | 9.6% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +2.9% | +13.3% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | -12.6 pp | -5.4 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +8.8 pp | -0.2 pp | 8th highest of 21 |
| EV / EBITDA | 7.5× | 14.1× | 2nd cheapest of 7 |
| Net debt / EBITDA | -0.7× | -0.4× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 19.1× | -5.4% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |